NCT02913716View on ClinicalTrials.gov

A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Healthy Subjects
Interventions
DRUG

defactinib

Single oral dose of 400 mg \[14C\]-defactinib

All Listed Sponsors
lead

Verastem, Inc.

INDUSTRY

NCT02913716 - A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects | Biotech Hunter | Biotech Hunter